Pharmaceutical Executive, Sep 1, 2013 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Sep 1, 2013
Features
Promotional Review Committees: How to Achieve High Performing Teams
By Arthur Lazarus
What it takes for promotional review teams to function at their best and avoid costly mistakes.
Making Sense of the Sunshine Act
By Shantanu Agrawal
The Sunshine Act's Open Payments spending disclosure program is now live. The government's lead compliance officer explains how it will work.
Crunch TIme for Emerging Markets
By William Looney
Normal service will be resumed as soon as possible.
Country Report
Country Report: Indonesia
Ask Indonesians about a bad experience in medical care and each will have a story to tell. The poor state of Indonesia's healthcare system has turned "improving quality" into the top priority of the government of Indonesia. Better quality of care has become especially important as the fourth most populated country in the world moves forward with its plans to achieve universal healthcare coverage.
Column
The Art and Science of Creating Discomfort
By Al Topin
What does a challenger brand need to do?
The Drug Combination Competition
Companies are leveraging combinations of drugs and other products to gain competitive advantage and market share.
Biopharma Innovation in Trouble?
By Jill Wechsler
Rising costs will mean a drop in anticipated NDAs next year, reflecting an ever-longer and more costly drug-development process that is squeezing pharma investment in R&D.
Pathology in the Era of Personalized Medicine
With their knowledge of molecular genetics, Pathologists are transforming the way healthcare is provided.
Share of Screen: Prioritizing Electronic Health Records
By Ben Comer
Are electronic health records a viable channel for engagement? Ben Comer reports.
T-TIPing the Balance in Industry's Favor
By Reflector
By the start of 2014, industry expects to have a clearer idea of how far the US-EU free trade pact is going.
From the Editor
Trying to Control Pharma Costs?
By William Looney
A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, lifealtering diseases.

ADVERTISEMENT

Click here